-
DISCOVERY
-
PRECLINICAL
-
PHASE 1
-
PHASE 2
-
PHASE 3
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
A first-in-class candidate to slow the progression of Alzheimer’s disease
ALZT-OP3
We are developing ALZT-OP3, a novel, next-generation oral candidate to treat a range of neurodegenerative diseases. We expect to file an investigational new drug (IND) application to begin clinical development of ALZT-OP3 in 2021.
Microbiome Exploratory Study